Back to search
T-Cell and NK-Cell Neoplasm
Clinical trial pipeline · Data from ClinicalTrials.gov
See which T-Cell and NK-Cell Neoplasm trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which T-Cell and NK-Cell Neoplasm trials you may qualify forThe goal of this clinical research study is to learn about the safety of giving immune cells called natural killer (NK) cells with chemotherapy to patients with…
This trial represents a single institution phase I/II pilot study with the primary objective of establishing the safety and feasibility of generating and infusi…
This phase II clinical trial studies how well personalized natural killer (NK) cell therapy works after chemotherapy and umbilical cord blood transplant in trea…
CD70 is a promising target for immunotherapy because it is overexpressed in T-cell lymphoma (TCL) and acute myeloid leukemia (AML) tumor cells but is found in d…
The purpose of this clinical trial is to assess the feasibility, safety and efficacy of universal CAR T cells based on 4SCAR7U design against CD7-positive hemat…
The purpose of this study is to test any good and bad effects of the study drug called ruxolitinib. Ruxolitinib works by blocking a protein called JAK. JAK work…
This phase II trial studies the effect of duvelisib or CC-486 and usual chemotherapy consisting of cyclophosphamide, doxorubicin, vincristine, etoposide, and pr…
Effective treatment options for relapsed/refractory acute myeloid leukemia (AML) and T-cell non-Hodgkin lymphoma (T-NHL) represent a significant unmet medical n…